These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 14300626)

  • 1. [CHANGES OF BLOOD PROTEIN FRACTIONS IN PATIENTS WITH OVARIAN CANCER UNDERGOING CHEMOTHERAPY].
    KULIK GI; DANILENKO LP
    Vopr Onkol; 1965; 11():30-4. PubMed ID: 14300626
    [No Abstract]   [Full Text] [Related]  

  • 2. [Changes of the serum protein pattern after antiblastic chemotherapy in advanced stages of ovarian carcinoma].
    Gilardi G; Vertova A
    Arch Ostet Ginecol; 1966; 71(6):681-94. PubMed ID: 5999513
    [No Abstract]   [Full Text] [Related]  

  • 3. [Changes in the serum protein picture in metastasizing ovarian carcinoma under the influence of cytostatic therapy (endoxan)].
    MURKEN J
    Z Geburtshilfe Gynakol; 1962 Jul; 159():90-8. PubMed ID: 14477377
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of the incubation in vitro with sorbents on serum proteomic pattern and cytokine concentration in cancer patients during chemotherapy--preliminary results.
    Piccolomini F; LouWratten M; Sereni L; Balestreri E; Donadio E; Felicioli A; Felicioli R; Donadio C
    Biomed Pharmacother; 2006 Sep; 60(8):463-7. PubMed ID: 16930936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nursing of a patient with ovarian cancer undergoing postoperative chemotherapy].
    Taguchi A; Nakane N; Watanabe M; Matsumoto S; Nakamura M
    Kango Gijutsu; 1989 Mar; 35(4):400-3. PubMed ID: 2754874
    [No Abstract]   [Full Text] [Related]  

  • 6. [Changes in the serum protein pattern after antiblastic chemotherapy of ovarian carcinoma in advanced stage].
    Gilardi G; Vertova A
    Minerva Ginecol; 1967 Aug; 19(16):799-801. PubMed ID: 5605080
    [No Abstract]   [Full Text] [Related]  

  • 7. [Protein fractions in the blood of patients with laryngeal cancer].
    Bodea I; Bolchiş P; Elias M
    Otorinolaringologie; 1969; 14(3):217-21. PubMed ID: 5356066
    [No Abstract]   [Full Text] [Related]  

  • 8. [Nursing care for ovarian cancer patients with intraperitoneal chemotherapy].
    Lu YY; Chou JF; Tsao LI; Liang SY; Wu SF
    Hu Li Za Zhi; 2015 Feb; 62(1):87-91. PubMed ID: 25631188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer.
    Weinberg LE; Rodriguez G; Hurteau JA
    J Surg Oncol; 2010 Mar; 101(4):334-43. PubMed ID: 20187069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of chemotherapy in the management of advanced ovarian cancer.
    ABOUL-NASR AL
    Cancer Chemother Rep; 1961 Jul; 13():185-91. PubMed ID: 13681065
    [No Abstract]   [Full Text] [Related]  

  • 11. Biochemical blood studies in patients with ovarian carcinoma treated with C-283. 3. Immunoelectrophoresis of serum proteins.
    Dobryszycka W; Gerber J; Jabloński K; Bec I
    Arch Immunol Ther Exp (Warsz); 1972; 20(3):367-73. PubMed ID: 4115628
    [No Abstract]   [Full Text] [Related]  

  • 12. [Alterations of mitochondrial DNA in ovarian cancer patients with and without chemotherapy].
    Shi HH; Pan LY; Yang XY; Yuan Y; Yu XD
    Zhonghua Fu Chan Ke Za Zhi; 2005 Jul; 40(7):469-71. PubMed ID: 16080874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis.
    Dutta T; Sharma H; Kumar L; Dinda AK; Kumar S; Bhatla N; Singh N
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):427-35. PubMed ID: 15906030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New strategies for the treatment of ovarian cancer.
    Robinson E; Fisher N; Stamelos V; Redman C; Richardson A
    Biochem Soc Trans; 2014 Feb; 42(1):125-9. PubMed ID: 24450639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal antineoplastic agents in the management of ovarian cancer.
    Tropé C; Kaern J; Vergote I
    Eur J Surg Suppl; 1991 May; (561):83-6. PubMed ID: 1720054
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemotherapy in epithelial ovarian cancer.
    Pignata S; Cannella L; Leopardo D; Pisano C; Bruni GS; Facchini G
    Cancer Lett; 2011 Apr; 303(2):73-83. PubMed ID: 21353386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer.
    Tas F; Yildiz I; Kilic L; Ciftci R; Keskin S; Sen F
    Am J Ther; 2016; 23(3):e670-9. PubMed ID: 23782755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy in the treatment of ovarian cancer. (the cancer-chemotherapy-sensitvity-test).
    Limburg H
    Nihon Sanka Fujinka Gakkai Zasshi; 1969 Aug; 21(8):907-8. PubMed ID: 5388529
    [No Abstract]   [Full Text] [Related]  

  • 19. Affino-immunoelectrophoresis of haptoglobin with wheat germ agglutinin. Diagnostic significance in ovarian carcinoma.
    Katnik I; Gerber J; Dobryszycka W
    Arch Immunol Ther Exp (Warsz); 1987; 35(4):547-52. PubMed ID: 3439855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Counterpoint: Is There Still a Role for Intraperitoneal Platinum Therapy in Ovarian Cancer? There Is No Role for IP Chemotherapy in Ovarian Cancer.
    Ozols RF
    Oncology (Williston Park); 2018 Feb; 32(2):75, 77-9. PubMed ID: 29492948
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.